Significance of Angiogenesis Determination in Pediatric Solid Tumors
Safinaz A. El-Habashy,
Ahmed Samy Khalifa,
Salah S. Abdel Hadi ,
Nader AL Dahaba ,
Maha A. Rasheed
Tahany R. Ilias
Fifty one patients (27 boys and 24 girls) with solid tumors whose ages ranged between 2 and 168 months were enrolled. Serum Vascular endothelial growth factor by Sandwich Enzyme linked immunosorbent assay was determined for all patients before any treatment and for 17 patients of them while in remission 6-9 months post therapy. Tissue biopsy was obtained for micro vessel count (MVC) determination by staining endothelial cells for factor VIII-related antigen with the use of a standard immunoperoxidase technique. Before therapy, median concentration of serum VEGF was significantly increased in solid tumors` patients when compared to control group (p<0.001) with non significant relation to tumor type. Also, patients with different histopathologic diagnoses had comparable median MVC (tissue angiogenesis) with non significant intergroup variability. Serum VEGF increased significantly in patients with neuroblastoma (n = 19) compared to those with ganglioneuroma (n = 6) while MVC values were comparable. When patients with metastatic cancer (n = 15) were compared to those with localized disease (n = 30), median VEGF levels and MVC were slightly higher in the former group, the difference did not reach statistical. In all cancer patients (n = 45), VEGF values correlated with MVC (r = 0.33, p = 0.022). After treatment, serum concentrations of VEGF dropped significantly (p<0.001) but still higher than control values (p =<0.001). Estimated OS and EFS of the whole group with malignant solid tumors patients were 86 and 72%, respectively. Serum VEGF did not correlate with outcome for the whole group of patients. Cox regression revealed that MVC (p<0.001) and stage of cancer (p<0.001) were highly associated with EFS of patients with embryonal tumors. Tumor angiogenesis can be indirectly assessed in vivo by serum VEGF measurement which is correlated with tissue MVC. Also, monitoring the levels of VEGF in patients with cancer may prove to be a useful marker for tumor status and response to treatment.
Angiogenesis, neovascularization, is the process leading to formation of new blood vessels (Folkman, 1992). Angiogenesis is a crucial mechanism required for a number of physiological and pathological events. In physiological conditions, angiogenesis is a highly regulated phenomenon. It normally occurs during embryonic development, wound healing and the menstruation cycle. Unregulated angiogenesis is seen in pathological conditions, such as psoriasis, diabetic retinopathy and cancer (Tonini et al., 2003). The most dramatic angiogenesis-dependent disease is cancer. During tumor growth, angiogenesis is required for proper nourishment and removal of metabolic wastes from tumor sites (Gasparini and Harris, 1995).
Formation of solid tumors requires coordination of angiogenesis with continued tumor cell proliferation. However, despite such neovascularization, hypoxia is persistent and frequently found in tumors at the time of diagnosis. Hypoxia arises early in the process of tumor development because rapidly proliferating tumor cells outgrow the capacity of the host vasculature. Tumors with low oxygenation have a poor prognosis and strong evidence suggests that this is because of the effects of hypoxia on malignant progression, angiogenesis, metastasis and therapy resistance (Tonini et al., 2003). Although hypoxia inhibits cell proliferation and eventually cell death, hypoxia also provides angiogenic and metastatic signals, thus allowing prolonged survival in the absence of oxygen and generation of a persistent angiogenic signal (Dulak and Jozkowicz, 2003; Wouters et al., 2003).
Neoplastic cells may produce several angiogenic peptides, but vascular endothelial cells also secrete growth factors and cytokines that stimulate tumor cells proliferate or attract and stimulate inflammatory cells (Hamada et al., 2000). The extent of vasculature assessed by immunohistochemistry and micro vessel counting predicts prognosis in many tumor types (Weidner, 1995). Urine and other body fluids of cancer patients have shown to contain endothelial chemokinetic and proliferative activity (Li et al., 1994).
Tumor angiogenesis can be indirectly assessed in vivo by angiogenic factor measurements in body fluids. There has been much interest in the possible use of angiogenic factors as tumor markers to evaluate tumor status, monitor response to therapy and/or predict outcome (Nguyen, 1997). Micro vessel counting in cancer tissues after immunohistochemical staining remains the reference method of angiogenesis assessment (Weidner, 1995). The present study was conducted to define the role of angiogenesis in pediatric solid tumors, to find out any relation between angiogenesis markers and disease stage, number of metastases and volume of involvement, to evaluate any predictive value of serum angiogenic markers on possibility of response to cytotoxic therapy and to investigate the usefulness of VEGF as a possible prognostic factor in conjunction with the more established parameters.
MATERIALS AND METHODS
Study population: During the period January 2000 till May 2004, 51 patients with solid tumors were enrolled. They were registering to Pediatric Department of NCI (40 patients), Cairo University and Pediatric Hematology/Oncology Clinic (11 patients), Ain Shams University. They were 27 boys and 24 girls whose ages ranged between 2 and 168 months. Twenty healthy children were recruited to determine normal concentration of serum vascular endothelial growth factor (VEGF). A verbal consent was obtained from guardians prior inclusion in study.
Patients groups: Cancer patients were diagnosed according to standard histopathologic, immunohistochemical, radiomaging and tumor markers relevant to each type of cancer. Six categories were identified;
Malignant solid tumors: Nineteen patients with Neuroblastoma (NB), 13 with Wilms tumor (WT), 8 Rhabdomyosarcoma (RMS), 3 Retinoblastoma (RB) and 2 with Hepatoblastoma (HB).
Benign solid tumors: Six patients with Ganglioneuroma (GN). Age and sex distribution of patients is shown in Table 1.
Pathologically proven primary solid tumors.
Performance more than 60%.
Life expectancy more than 6 month.
Unified treatment policy and protocols.
Control group: Twenty normal infants and children, 12 boys and 8 girls whose mean age was 38.4 (±30.0) months were included as controls. They were recruited from siblings of patients attending Outpatient Clinic, Childrens Hospital, Ain Shams University.
All patients were subjected to:
||Complete history taking with particular emphasis on initial
presentation, duration of illness and constitutional symptoms.
||Thorough clinical examination laying stress on presence of metastases
and disease particulars as hemihypertrophy and aniridia in Wilms tumor,
precocity in hepatoblastoma. Blood pressure was checked being important
for patients with Wilms tumor, neuroblastoma and any abdominal masses with
possible compressing manifestations.
||Staging systems: INSS for neuroblastom (Brodeur et al., 1993;
Castelbery et al., 1994), NWTS-3 for Wilmstumor (D;Angio et al.,
1989) IRS for rhabdomyosarcoma (Lawrence et al., 1987), St. Jude
Children's Research Hospital clinical staging system for retinoblastoma
(Howarth et al., 1980; Messmer et al., 1991) and PRETEXT staging
for hepatoblastoma (Brown et al., 2000).
||Radioimaging studies; computerized tomography (C/T) scan to assess tumor
size and bone scan for presence of metastasis.
||Treatment: Patients in each tumor type received the same protocol. Response
to treatment was assessed according to World Health Organization (WHO) criteria
for definition of objective of response.
Routine laboratory requests:
||Complete blood count: Coulter-Microdiff 18.
||Renal function tests: Blood urea nitrogen (BUN) (Patton and Crouch, 1977)
and serum creatinine (Höuöt, 1985).
||Liver function tests: Alanine transaminase (ALT) and aspartate transaminase
(AST) calorimetrically (Reitman and Frankle, 1957) and total serum bilirubin
(Jendrassic and Grof, 1938).
||Lactate Dehydrogenase (LDH) using colorimetric endpoint technique (Henry,
1974) and Neuron Specific Enolase (NSE) using ELISA technique (Sell, 1990)
for neuroblastoma patients and alpha fetoprotein (α-FP) for hepatoblastoma
Angiogenic marker: Serum Vascular endothelial growth factor by Sandwich
Enzyme linked immunosorbent assay (ELISA), (Dosquet et al., 1997), Kit
supplied by Oncogeny Research Products (84 Rogers Street, Cambridge, UK). Serum
VEGF was determined for all patients before any treatment and for 17 patients
(11 NB and 6 WT) while in remission 6-9 months post therapy.
Tissue biopsy: Needle biopsy was obtained for pathological diagnosis and then open biopsy at time due for operative intervention according to protocol of therapy. Tumor specimens from all patients were available for micro vessel density determination. Blood vessels were highlighted by staining endothelial cells for factor VIII-related antigen (DAKO Corporation, Carpinteria, CA, USA) with the use of a standard immunoperoxidase technique (Pinkus et al., 1986 ).
Statistical analysis: Statistical analysis was performed using SPSS version 10. Statistical significance of differences between variables was analyzed by Mann-Whitney, Kruskal-Wallis and Wilcoxon rank tests. Cox regression models were used to explore association between angiogenic makers as well as other known prognostic factors (age, stage, favorable pathology and tumor markers) and survival rates. Cutoff level of b-FGF was defined as value above the 95th percentile of normal controls. Events were defined as progression of disease under treatment or recurrence after first complete remission. Survival was calculated from first day of diagnosis until last contact, defined as date of death or date of last follow up.
Patients characteristics: Patients were matched to the control group with respect to mean age and sex distribution (Table 1). Compared to each other, patients with hepatoblastoma were the youngest while those with ganglioneuroma were the eldest.
Disease characteristics: Embryonal tumors constituted 82% (37/45) of cases with malignant solid tumors, whilst RMS patients presented the rest 18% (8/45). Six patients with ganglioneuroma were included as an example of benign solid tumor for angiogenesis comparison. With respect to disease stage, 36 out of 45 (80%) of patients with malignant solid tumors presented at late stages III and IV. With regard to metastasis sites number, 53.3% (8/15) had only one metastatic site whereas 46.7% had more than one site.
Tumor size: Tumor size as determined by C/T scan (multiplying maximum 2 dimensions) was variable among studied patients; in NB the mean was 101(±70.4) cm2, in WT was 144.8±65 cm2 while in RMS 300±169.7 cm2. In GN, it was 552.5±59.6 cm2. Individual values in HB were 72 and 108 cm2.
Tumor pathology: According to Shimada, six out of 19 (31.5%) NB patients
were having stroma-rich malignant tissues. Favorable histology was diagnosed
in 9 of 13 (69%) of WT group. Histologic subtypes recognized in RMS were embryonal
in 4, alveolar in 2 and undifferentiated in 2.
|| Age and gender distribution of patients and control group
||Serum Vascular Endothelial Growth Factor (VEGF) in patients
||Mean Micro vessel Count (MVC/X400 field) among studied cancer
|| Angiogenic markers in Neuroblastoma versus Ganglioneuroma
Those with hepatoblastoma were both of fetal subtype.
Tumor markers: Neuroblastoma patients; serum neuron specific enolase was available for 17 patients at diagnosis with a median of 81 (range, 5.8-522.9) ng mL-1. Serum Lactate dehydrogenase was determined for 15 NB patients with a median of 1620 (761-1707.6) U mL-1. In GN, median NSE was 13 (11-14) ng mL-1 and LDH was 732 (504-940) U mL-1. Hepatoblastoma patients were tested for alpha fetoprotein levels (αFP) which were 1710 and 3200 m I U mL-1.
||Serum Vascular Endothelial Growth Factor (VEGF) in patients
with metastatic versus non-metastatic disease
||High MVC in favorable histology Wilms tumor, average count
||Low MVC in stroma-rich neuroblastoma, average count 11/X400
Serum angiogenesis: Before therapy, median concentration of serum VEGF was
highly significantly increased in solid tumor patients when compared to control
group (p<0.001). Yet, there was non significant difference in the mean serum
VEGF between patients subgroups (p = 0.36) (Table 2).
Tissue angiogenesis (MVC): Examples of tumors with high and low micro
vessel count (Table 3) as delineated by fVIII-related antigen
staining are shown in Fig. 1-3. Patients
with different diagnoses had comparable median MVC.
||Intermediate MVC in hepatoblastoma, average count 19 /X400
||Serum VEGF before and after therapy
||Overall survival of malignant solid tumors patients in relation to serum VEGF levels
On comparing NB and GN patients, serum VEGF was found to be significantly elevated
in the former group (Table 4). With respect to MVC, there
was non significant difference between patients with NB and those with GN.
||Event-free survival of malignant solid tumors patients in
relation to serum VEGF levels
When patients with metastatic cancer (n =15) were compared to those with non
metastatic disease (n = 30), median VEGF levels and MVC tended to be higher
in the former group, the difference did not reach statistical (Table
After treatment (chemotherapy and/or surgery), mean serum concentrations of VEGF in 17 patients (11 NB and 6 W T) dropped significantly (from Mean±SD, median of 484.3±149.3, 403.6 pg mL-1 to 320.1±44.8, 328.9 pg mL-1; p<0.001) as shown Fig. 4 but still significantly higher than control values (p<0.001).
In healthy children, serum VEGF concentrations did not show any correlation with age (r = 0.09, p = 0.65). No significant correlation was observed between VEGF and either age (r = 0.106, p = 0.46) or tumor size (r = 0.08, p = 0.62) or metastasis number (r = 0.144, p = 0.32). In all cancer patients (n = 45), VEGF values correlated with MVC (r = 0.33, p = 0.022). In NB patients, VEGF correlated with LDH levels (r = 0.58, p = 0.014) and MVC correlated with NSE (r = 0.527, p = 0.02).
Follow up and survival analysis: Median follow up of the whole group was 18 months (range 6-44 months). At time of survival analysis, 31 patients were alive, with a mean follow up of 38 months (95th confidence interval 33.6-42.5) and five patients had died 6-30 months after diagnosis. Estimated OS and EFS of the whole group with malignant solid tumors patients were 69 and 64%, respectively.
Serum VEGF did not correlate with outcome for the whole group of patients;
OS and EFS for patients with normal serum VEGF (n = 8) were 100 and 64.5% in
comparison to 83.3% and 62% for those with elevated values; p = 0.4 and 0.5,
respectively (Fig. 4-5).
Cox regression revealed that MVC (p<0.001) and stage of cancer (p<0.001)
were highly associated with EFS of patients with embryonal tumors (all patients
but rhabdomyosarcoma). When patients with RMS were included, such association
was not observed, but the probability for serum VEGF was borderline (p = 0.65)
Currently, the prognosis of patients with cancer is judged by knowledge of
probable length of survival and of incidence of recurrence for given stage.
Therefore, the search for some marker that is invariably associated with good
or poor prognosis is continuing, so that therapy can be still more accurately
and appropriately adjusted to needs of a particular patient. This was considered
while planning for the current study. To date, little is known regarding the
role of angiogenic factors in pediatric solid tumors, a matter extensively investigated
in adult cancer. To our knowledge, this is the first research registered in
Egypt depicting the value of angiogenesis assessment in some pediatric solid
tumor with respect to outcome. In the current cohort, serum VEGF concentrations
were increased in pediatric patients with solid tumors when compared to healthy
subjects (p<0.001). This result goes in agreement with others; Bredel
et al. (1997), Tabone et al. (2001), Pavlakovic et al. (2001),
Bentas et al. (2003), Barthlen et al. (2003), El-Houseini et
al. (2004), Sampath et al. (2004), Dina et al. (2005) and
Sun et al. (2005).
Vascular endothelial growth factor promotes growth of malignant cells in several ways: by enhancing delivery of oxygen and nutrients through new vessel formation; by enriching the extracellular matrix through increased vessel permeability; and, in some circumstances, by a direct receptor-mediated effect. It is a mitogen for endothelial cells that promotes as well their survival in vitro and in vivo (Parikh and Ellis, 2004).
Serum VEGF levels were elevated in the present cohort with lack of correlation with type of malignant solid tumor (p = 0.36). This is supported by the finding of a non significant difference in median micro vessel count (MVC, p = 0.63) in various histologic subtypes of those patients. Similarly, El-Houseini et al. (2004) (Ewing's sarcoma, osteosarcoma, neuroblastoma and rhabdomyosarcoma), Yamamoto et al. (1996) (breast and gastric cancer) and Dirix et al. 1997 (colorectal, breast, ovarian and renal carcinoma) found that the rate of elevation of serum VEGF was not related to the tumor type.
To further explore the significance of angiogenesis in malignant solid tumors, we compared patients with NB versus those with GN regarding serum and tissue angiogenic markers. Those with NB displayed higher serum VEGF but MVC was comparable to those with GN (p = 0.005, p = 0.257, respectively). The latter result might be due to lower MVC in patients with NB as tissue specimens were obtained after chemotherapy effect. Our result might indicate the importance of serum VEGF as a tumor marker differentiating benign from malignant solid tumors. In addition to its effect on angiogenesis, VEGF may affect neuroblastoma cell growth directly and could be an autocrine growth factor (Langer et al., 2000).
The capacity of tumor cells to induce angiogenesis does not always correlate with malignancy and there is considerable confusion in the literature about this fact. Adrenal adenoma, for example, is a benign tumor that is highly angiogenic (Folkman, 1990). Contrary to other types of cancer, pancreatic endocrine tumours are highly vascularised, but poorly angiogenic tumours. As they progress, VEGF expression is lost and MVD significantly decreases. The regulation of hypoxia-inducible factor signaling appears to be specific in pancreatic endocrine tumors (Couvelard et al., 2005). However, patients with high grade malignancies, being characterized by fast progression, were found to have about five times higher VEGF serum levels than patients with low-grade sarcomas or lymphomas (Dirix et al., 1997). The levels of VEGF were significantly higher in high-grade astrocytomas than in nonastrocytic tumors in the series of Sampath et al. (2004).
A clinically relevant observation in the current work was that patients with metastatic disease exhibited higher serum VEGF and MVC than those with localized disease (p = 0.54 and p = 0.4, respectively), although difference did not reach statistical significance. The percentage of elevated serum VEGF above cut-off value among patients with metastatic disease (87%) was comparable to that of localized disease (87%, p = 0.58). This result was not surprising because most studied patients with localized disease (80%) belonged to late stages (stage III in 16 out of 20). This observation supports the role of angiogenic factors in advanced cancer, not only metastatic but also locally disseminated disease.
Kayton et al. (1999) reported that absolute serum VEGF levels increased as primary tumors grow and VEGF production was significantly associated with tumor metastasis in both clinical and experimental Wilms tumor. Significantly higher expression levels of VEGF were found in advanced-stage neuroblastoma (stages 3 and 4) compared to low-stage tumors (stages 1 and 2) (Eggert et al., 2000). Serum VEGF was suggested to serve as a diagnostic tool in advanced stage NB (Fakhari et al., 2002). Similar results were reported by El-Houseini et al. 2004 in a group of children with malignant solid tumors (NB, RMS, Ewing's sarcoma, and osteosarcoma). A tendency of higher vessel densities in retinoblastoma presenting with metastasis (stage IV) at time of diagnosis was observed by Rossler et al. (2004). VEGF was expressed in 70% of Langerhans cell histiocytosis patients. All the multisystem lesions were VEGF producers (Dina et al., 2005). Clinically aggressive favorable histology Wilms tumor displayed progressive alteration in p53/TSP-1 status and upregulation of VEGF. Such alteration was observed in the unfavorable histology tumor, but was absent from the standard-risk favorable histology tumor. Xenografts from clinically aggressive tumors displayed brisk neoangiogenesis and yielded lung metastases (Huang et al., 2002).
There is a direct correlation between the number of capillaries visible in
histologic sections of tumors and their metastatic behavior. Reports indicate
that counting the number of capillaries per square millimeter in the most highly
vascularized areas of a tumor section provides an important independent variable
predicting prognosis of patients with lung cancer (Macchiarini et al.,
1992) or breast cancer (Bosari et al., 1992). In patients with node-positive
breast carcinoma, MVC were considerably higher in tumors from patients who experienced
distant recurrence than in those who did not, although the difference did not
reach statistical significance (Bosari et al., 1992).
In the current study, after successful therapy and attaining a state of complete remission, levels of VEGF decreased significantly to values (p = 0.003) which were still higher than controls (p<0.001). Drop of serum VEGF after therapy suggests that the source of which might be present in the tumor tissue. Similarly, results of Pavlakovic et al. (2001), showed that elevated pretherapy levels of b-FGF and vascular endothelial growth factor (serum and urine) declined, but to levels present in healthy subjects. Lin et al. (1995) found that high postoperative b-FGF level may indicate recurrence or persistence of WT. Thus, monitoring the levels of VEGF and possibly other angiogenic peptides, in the urine, serum, or CSF of patients with cancer may prove to be a useful marker for tumor status and perhaps prognosis. Tumor cells may overexpress angiogenic factors, may mobilize angiogenic proteins from the extracellular matrix, may recruit host cells such as macrophages which then produce their own angiogenic molecules/or may engage in a combination of these processes (Folkman, 1997). Measurement of various angiogenic factors in body fluids will most likely be useful as a monitor of therapy and/or predictor of outcome (Nguyen, 1997).
In adult cancer, removal of a primary colorectal adenocarcinoma clearly decreased individual serum levels of VEGF (Dirix et al., 1997). The same observation was made by Yamamoto et al. 1996 in primary breast cancer. Furthermore, serum VEGF appears to be a useful marker for monitoring the clinical course after surgery for breast (Yamamoto et al., 1996) and ovarian cancers (Yamamoto et al., 1997).
Contrary to what was expected, no correlation was observed in the current study between tumor size (by computed tomography) and either VEGF or MVC whether in solid tumor group or each patients group individually. The limited number of patients evaluated in this pilot study must be borne in mind, but solid tumor heterogeneity of vascularity could not be ignored.
A significant correlation was observed in the current work between serum VEGF and tissue MVC (r=0.330) which might implicate that serum VEGF determination could be used as a surrogate marker of tumor angiogenesis. Ghanem et al., 2003 concluded that VEGF and its receptor Flt-I protein expression were closely related to MVC in nephroblastoma patients. Serum VEGF concentration in 137 breast cancer patients was associated with microvessel density wherein patients with less than 100 microvessels per mm2, 2.9% had elevated serum VEGF. In those with more than 150 microvessels per mm2 42.9% had an elevated VEGF serum levels (Yamamoto et al., 1996). Indirectly, VEGF serum levels might thus be related with prognosis as high MVC has been associated with shortened survival in many studies (Gasparini and Harris, 1995).
Present study has demonstrated that serum VEGF did not correlate with outcome for the whole group of patients. In the study of Tabone et al. (2001) conducted on children with solid tumors (NB, WT, osteosarcoma and Ewings sarcoma), the estimated event-free survival was 71% in case of normal serum VEGF (n = 20) versus 38% (n = 19) for those with high levels.
Cox regression analysis revealed that MVC and stage of cancer were the only among prognostic factors that were independently highly associated with event-free survival of current patients with embryonal tumors (NB, WT, HB and RB, N = 37). Such an association was not observed when patients with RMS were included. The independence of MVC from several other prognostic factors could further enhance its clinical usefulness. The practical implication is that, the microvessel quantitation will have to be weighed with the other prognostic indicators.
In the study of Abramson et al. (2003), Kline and Sevier (2003) increased
MVC was found to identify Wilms tumor patients at risk for relapse, especially
those with favorable histology tumors. In the latter study, MVC was the only
predictor of relapse when compared to age, sex, tumor weight and histology.
Ghanem et al. (2003) reported that MVC was predictive of clinical progression
in nephroblastoma patients. Intratumoral vessel density was also positively
related with Event Free Survival (EFS) in childhood embryonal rhabdomyosarcoma
(RMS); mean EFS was 20.8 months (Diniz et al., 2004). Children with malignant
liver tumors, especially with hepatocellular carcinoma, may have extensive angiogenesis,
reflected by significant expression of VEGF and high MVC, that induced a rapid
tumor growth and led to a poor prognosis (Sun et al., 2005).
In pediatric patients with another solid tumor, complete and partial response rate to therapy was significantly higher in VEGF-negative patients than in the VEGF-positive non Hodgkin lymphoma patients (Hazar et al., 2003). However, vascular parameters adequately determined by a computerized system in neuroblastoma were not predictive of survival and neither disseminated nor local relapses were influenced by the angiogenic characteristics of the tumors as reported by Canete et al. (2000).
1: Abramsonm, L.P., P.E. Grundy, A.W. Rademaker, I. Helenowski and M. Cornwell et al., 2003. Increased microvascular density predicts relapse in Wilms' tumor. J. Pediatr. Surg. Mar., 38: 325-330.
2: Barthlen, W., D. Flaadt, R. Girgert, J. Conzelmann and P. Schweizer et al., 2003. Significance of heparin-binding growth factor expression on cells of solid pediatric tumors. J. Pediatr. Surg. Sep., 38: 1296-1304.
3: Bentas, W., W.D. Beecken, W. Glienke, J. Binder and H. Schuldes, 2003. Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors. Urol. Res. Feb., 30: 390-393.
4: Bosari, S., A.K. Lee, R.A. DeLellis, B.D. Wiley, G.J. Heatley and M.L. Silverman, 1992. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol., 23: 755-761.
5: Brodeur, G.M., J. Pritchard, F. Berthold, N.L. Carlsen and V. Castel et al., 1993. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol., 11: 1466-1477.
6: Bredel, M., R.D. Pollack, J.W. Campbell and R.L. Hamilton, 1997. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high grade gliomas. Clin. Can. Res., 3: 2157-2164.
7: Brown, J., G. Perilongo, E. Shafford, J. Keeling and J. Pritchard et al., 2000. Pretreatment prognostic factors for children with hepatoblastoma-- results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur. J. Cancer, 36: 1418-1425.
8: Castleberry, R.P., J.J. Shuste and E.I. Smith, 1994. The pediatric oncology group experience with the international staging system criteria for neuroblastoma. J. Clin. Oncol., 12: 2378-2381.
9: Canete, A., S. Navarro, J. Bermudez, A. Pelli and V. Castel, 2000. Llombart-Bosch A: Angiogenesis in neuroblastoma: Relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J. Clin. Oncol., 18: 27-34.
10: Couvelard, A., D. O'Toole, H. Turley, R. Leek and A. Sauvanet et al., 2005. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer, 92: 94-101.
11: D'Angio, G.J., N. Breslow, J.B. Beckwith, A. Evans and H. Baum et al., 1989. Treatment of Wilms' tumor: Results of the third national wilms' tumor study. Cancer, 64: 349-360.
12: Diniz, G., S. Aktas, R. Ortac, A. Erbay, C. Vergin and M. Ergin, 2004. Alternative prognostic factors in pediatric embryonal rhabdomyosarcoma: Nm23 expression, proliferative activity and angiogenesis. Turk. J. Pediatr., 46: 239-244.
13: Dina, A., V. Zahava and M. Iness, 2005. The role of vascular endothelial growth factor in Langerhans cell histiocytosis. J. Pediatr. Hematol. Oncol., 27: 62-66.
14: Dirix, L.Y., P.B. Vermeulen, A. Pawinski, A. Prove and I. Benoy et al., 1997. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer, 76: 238-243.
15: Dosquet, C., M.C. Coudert, E. Lepage, J. Cabane and F. Richard, 1997. Are angiogenic factors, cytokines and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma. Clin. Cancer Res., 3: 2451-2458.
16: Dulak, J. and A. Jozkowicz, 2003. Antioxid. Redox Signal, 5: 123-132.
17: Eggert, A., N. Ikegaki, J. Kwiatkowski, H. Zhao, G.M. Brodeur and B.P. Himelstein, 2000. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res., 6: 1900-1908.
18: El-Houseini, M.E., S.A. Abdel-Azim, G.I. El-Desouky, S. Abdel-Hady, M.F. El-Hamad and A.M. Kamel, 2004. Clinical Significance of Vascular Endothelial Growth Factor (VEGF) in Sera of Patients with Pediatric Malignancies. J. Egypt Natl. Cancer, Inst., 16: 57-61.
19: Fakhari, M., D. Pullirsch, K. Paya, D. Abraham, R. Hofbauer and S. Aharinejad, 2002. Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J. Pediatr. Surg., 37: 582-587.
20: Folkman, J., 1990. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. (Bethesda), 82: 4-6.
21: Folkman, J., 1992. The role of angiogenesis in tumor growth. Cancer Biol., 3: 65-71.
22: Folkman, J., 1997. Antiangiogenic studies highlight similarities between solid tumors and leukemia suggest a novel approach to therapy. Trends Oncol. Hematol., 5: 51-52.
23: Gasparini, G. and A.L. Harris, 1995. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J. Clin. Oncol., 13: 765-782.
24: Ghanem, M.A., G.J. van Steenbrugge, M.K. Sudaryo, R.B. Mathoera, J.M. Nijman and T.H. van der Kwast, 2003. Expression and prognostic relevance of Vascular Endothelial Growth Factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J. Clin. Pathol., 56: 107-113.
25: Hamada, K., Y. Oike, N. Takakura, Y. Ito and L. Jussila et al., 2000. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood, 96: 3793-3800.
26: Hazar, B., S. Paydas, S. Zorludemir, B. Sahin and I. Tuncer, 2003. Prognostic significance of microvessel density and Vascular Endothelial Growth Factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk. Lymphoma, 44: 2089-2093.
27: Henry, J.B., 1974. Clinical Diagnosis and Management by Laboratory Methoodes. WB Saunders and Company, Philadelphia, PA, Pages: 365
28: Howarth, C., D. Meyer, H.O. Hustu, W.W. Johnson, E. Shanks and C. Pratt, 1980. Stage-related combined modality treatment of retinoblastoma: Results of a prospective study. Cancer, 45: 851-858.
29: Huang, J., S.Z. Soffer, E.S. Kim, A. Yokoi and J.T. Moore et al., 2002. p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. J. Pediatr. Surg, 37: 523-527.
30: Jendrassik, L. and P. Grof, 1938. Methods of serum total and direct bilirubin. Biochemistry, 2: 281-297.
31: Kline, N.E. and N. Sevier, 2003. Solid tumors in children. J. Pediatr. Nurs., 18: 96-102.
32: Kayton, M.L., D.H. Rowe, K.M. O'Toole, R.B. Thompson, M.A. Schwarz, C.J. Stolar and J.J. Kandel, 1999. Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor. J. Pediatr. Surg., 34: 743-747.
33: Lawrence, Jr. W., D.M. Hays, R. Heyn, M. Tefft and W. Crist et al., 1987. Lymphatic metastases with childhood rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study. Cancer, 60: 910-915.
34: Li, V.W., R.D. Folkerth, H. Watanabe, C. Yu and M. Rupnick et al., 1994. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet, 344: 82-86.
35: Lin, R.Y., P.A. Argenta, K.M. Sullivan and N.S. Adzick, 1995. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin. Cancer Res., 1: 327-331.
36: Langer, I., P. Vertongen, J. Perret, J. Fontaine, G. Atassi and P. Robberecht, 2000. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF receptors in human neuroblastomas. Med. Pediatr. Oncol., 34: 386-393.
37: Macchiarini, P., G. Fontanini, F. Squartini, C.A. Angeletti and M.J. Hardin, 1992. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340: 145-146.
CrossRef | PubMed | Direct Link |
38: Messmer, E.P., T. Heinrich, W. Hopping, E. de Sutter, W. Havers and W. Sauerwein, 1991. Risk factors for metastases in patients with retinoblastoma. Ophthalmology, 98: 136-141.
39: Nguyen, M., 1997. Angiogenic factors as tumor markers. Invest. New Drugs, 15: 29-37.
40: Patton, C.J. and S.R. Crouch, 1977. Spectrophotometric and kinetics investigation of the Berthelot reaction for the determination of ammonia. Anal. Chem., 49: 464-469.
CrossRef | Direct Link |
41: Pavlakovic, H., V. Von Schutz, J. Rossler, E. Koscielniak, W. Havers and L. Schweigerer, 2001. Quantification of angiogenesis stimulators in children with solid malignancies. Int. J. Cancer, 92: 756-760.
42: Parikh, A.A. and L.M. Ellis, 2004. The vascular endothelial growth factor family and its receptors. Hem. Onc. Clin. Nor. Am., 18: 951-971.
43: Pinkus, G.S., C.L. Ehteridge and E.M. O'Conner, 1986. Are keratin proteins a better tumor marker than epithelial membrane antigen? A comparative immunohistochemical study of various paraffin-embedded neoplasms using monoclonal antibodies. Am. J. Clin. Path, 85: 269-277.
44: Reitman, S. and S. Frankel, 1957. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28: 56-63.
CrossRef | PubMed | Direct Link |
45: Rossler, J., T. Dietrich, H. Pavlakovic, L. Schweigerer and W. Havers et al., 2004. Higher vessel densities in retinoblastoma with local invasive growth and metastasis. Am. J. Pathol., 164: 391-394.
46: Sampath, P., C.E. Weaver, A. Sungarian, S. Cortez, L. Alderson and E.G. Stopa, 2004. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Control, 11: 174-180.
Direct Link |
47: Sell, L.S., 1990. Cancer markers of the 1990s. Clin. Lab. Med., 10: 1-37.
48: Sun, X.Y., Z.D. Wu, X.F. Liao and J.Y. Yuan, 2005. Tumor angiogenesis and its clinical significance in pediatric malignant liver tumor. World J. Gastroenterol., 11: 741-743.
49: Tabone, M.D., J. Landman-Parker, B. Arcil, M.C. Coudert and I. Gerota et al., 2001. Are basic fibroblast growth fctor and vascular endothelial growth factor prognostic indicators on pediatric patients with malignant solid tumors?. Clin. Can. Res., 7: 538-543.
50: Tonini, T., F. Rossi and P.P. Claudio, 2003. Molecular basis of angiogenesis and cancer. Oncogene, 22: 6549-6556.
51: Weidner, N., 1995. Intratumor microvessel density as a prognostic factor in cancer. Am. J. Pathol., 147: 9-19.
52: Wouters, B.G., M. Koritzinsky, R.K. Chiu, J. Theys, J. Buijsen and P. Lambin, 2003. Modulation of cell death in the tumor microenvironment. Semin. Radiat. Oncol., 13: 31-41.
53: Yamamoto, Y., M. Toi, S. Kondo, T. Matsumoto and H. Suzuki et al., 1996. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res., 2: 821-826.
54: Yamamoto, S., I. Konishi, M. Mandai, H. Kuroda and T. Komatsu et al., 1997. Expression of Vascular Endothelial Growth Factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Br. J. Cancer, 76: 1221-1227.
55: Houot, O., 1985. Kinetic Determination of Creatinine. In: Interpretation of Clinical Laboratory Tests, Henny, J., G. Siest, F. Schiele and D.S. Young (Eds.). Biomedical Publications, California, USA., pp: 220-234